Loading...
Market
What will be the first disease targeted by a vaccine using Stanford's nanoparticle adjuvant by December 31, 2025?
2
Resolution / Starting Odds
COVID-19 • 25%
Influenza • 25%
HIV • 25%
Other • 25%
Press releases from vaccine manufacturers and peer-reviewed publications
Story
Stanford Develops Nanoparticle Adjuvant for Robust, Tunable Vaccine Immune Response
Aug 7, 2024, 06:41 PM
Researchers at Stanford Engineering have developed a new nanoparticle adjuvant that enhances the effectiveness of vaccines by producing more robust, longer-lasting, and tunable immune responses. This advancement, detailed in Science Advances, builds on existing vaccine additives and offers promising improvements in vaccine efficacy. The work by Ou Ben and Julie Baillet is part of ongoing efforts to improve vaccine performance, particularly in the context of COVID-19 and other diseases.
View original story
Similar markets
Influenza • 25%
Zika Virus • 25%
HIV • 25%
Other • 25%
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
Pathogen A • 25%
Pathogen B • 25%
Pathogen C • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
WHO • 25%
CDC • 25%
European Medicines Agency (EMA) • 25%
Other • 25%
Treatment of A. baumannii infections • 25%
Treatment of other bacterial infections • 25%
Pandemic preparedness • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Lymphoma • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Other • 25%
ACAM2000 • 25%
JYNNEOS • 25%
MVA-BN • 25%
Other • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%